An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects

• Drug: azithromycin (Zithromax)
  
  1. a single dose of azithromycin ER 2g
  2. 3-day regimen of azithromycin tablet 500mg
  Other Name: Zithromax
• Drug: azithromycin (Zithromax)
  
  1. 3-day regimen of azithromycin tablet 500mg
  2. a single dose of azithromycin ER 2g
  Other Name: Zithromax

• Group 1
  
  Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
  Intervention: Drug: azithromycin (Zithromax)
• Group 2
  
  Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
  Intervention: Drug: azithromycin (Zithromax)

Inclusion Criteria:

• Healthy volunteers.
• Male.
• 18-45 years old.
• BMI 17.5-30.5 kg/m2.

Exclusion Criteria:

• Alcohol, drug, smoke user.
• Sensitive to macrolide antibiotics class drug, parn or heparin-induced thrombocytopenia.
• Severe medical or psychiatric condition or laboratory abnormality.
• Blood donation.
• 12-ECG abnormal.
• Treatment with study drug; clinically significant.